Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma
18 Years
N/A
Both
Pancreatic Adenocarcinoma
Trial Information
Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma
Inclusion Criteria:
- Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at
MSKCC.
- Patient eligible for chemotherapy treatment.
- Prior surgery, chemotherapy and/or radiation therapy for pancreatic adenocarcinoma is
permitted.
- ECOG performance status 0-2.
- A minimum age of 18 years old.
Exclusion Criteria:
- Known to be HIV positive on antiretroviral therapy
- Prior organ allograft
- Any medical or psychiatric condition that may interfere with the ability to comply
with protocol procedures
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
isolating and enriching circulating tumorigenic cells
Outcome Description:
A 10 mL blood sample will be drawn from participants prior to starting chemotherapy treatment. circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients. During the 1 year following enrollment, in the setting of disease progression, a subsequent 10 mL blood sample may be drawn from participants prior to changing chemotherapy treatment.
Outcome Time Frame:
1 year
Safety Issue:
No
Principal Investigator
Kenneth Yu, M.D., M.Sc.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
11-141
NCT ID:
NCT01474564
Start Date:
November 2011
Completion Date:
November 2013
Related Keywords:
- Pancreatic Adenocarcinoma
- Blood draw
- pancreas
- Tumorigenic Cells
- 11-141
- Adenocarcinoma
- Adenocarcinoma, Mucinous
Name | Location |
|---|---|
| Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
